I-Mab and CSPC Pharma Announce Strategic Partnership for Long-acting GLP-1 Fc Program

I-Mab Biopharma and CSPC Pharmaceutical Group jointly announced a strategic partnership between the two companies. Under the partnership, I-Mab’s will grant an exclusive license to CSPC to develop I-Mab’s long-acting GLP-1 Fc program (TG103) in C https://www.biospace.com/article/releases/i-mab-and-cspc-pharma-announce-strategic-partnership-for-long-acting-glp-1-fc-program/